Home›Trabectedin

Trabectedin

Also known as: Yondelis

Alkylating DrugAlkylating Activity

Route: Intravenous

18 interactions on record

Trabectedin has 18 known drug interactions based on U.S. FDA drug labeling data. 18 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Boceprevir, Clarithromycin, Conivaptan. Patients taking Trabectedin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 18
Major: 18

Major (18)

Trabectedin + Boceprevir— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Clarithromycin— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Conivaptan— Strong CYP3A inhibitor. Avoid concomitant use with trabectedin or time administration carefully if short-term use necess…
Trabectedin + Indinavir— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Itraconazole— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Ketoconazole— 7 DRUG INTERACTIONS CYP3A inhibitors: Avoid concomitant strong CYP3A inhibitors ( 7.1 ) CYP3A inducers: Avoid concomitan…
Trabectedin + Lopinavir— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Nefazodone— Strong CYP3A inhibitor. Avoid concomitant use with trabectedin or time administration carefully if short-term use necess…
Trabectedin + Nelfinavir— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Phenobarbital— Strong CYP3A inducer. Avoid concomitant use with trabectedin.
Trabectedin + Posaconazole— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Rifampin— Strong CYP3A inducer decreased trabectedin systemic exposure by 31%. Avoid concomitant use with trabectedin.
Trabectedin + Ritonavir— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Saquinavir— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + St. John'S Wort— Strong CYP3A inducer. Avoid concomitant use with trabectedin.
Trabectedin + Telaprevir— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Telithromycin— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …
Trabectedin + Voriconazole— Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, …

Trabectedin + Boceprevir⚠️Major

Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, indinavir, lopinavir, ritonavir, boceprevir, nelfinavir, saquinavir, telaprevir, nefazodone, conivaptan) in patients taking YONDELIS.

Trabectedin + Clarithromycin⚠️Major

Trabectedin + Conivaptan⚠️Major

Strong CYP3A inhibitor. Avoid concomitant use with trabectedin or time administration carefully if short-term use necessary.

Trabectedin + Indinavir⚠️Major

Trabectedin + Itraconazole⚠️Major

Trabectedin + Ketoconazole⚠️Major

7 DRUG INTERACTIONS CYP3A inhibitors: Avoid concomitant strong CYP3A inhibitors ( 7.1 ) CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.2 ) 7.1 Effect of Cytochrome CYP3A Inhibitors Coadministration of YONDELIS with ketoconazole, a strong CYP3A inhibitor, increased systemic exposure of trabectedin by 66%. Avoid using strong CYP3A inhibitors (e.g., oral ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin, indinavir, lopinavir, ritonavir, boceprevir, nelfinavir, saquinavir, telaprevir, nefazodone, conivaptan) in patients taking YONDELIS. Drug Interactions Effect of Strong CYP3A Inhibitors on Trabectedin Coadministration of multiple doses of ketoconazole (200 mg twice daily for 7.5 days) with a single dose of YONDELIS (0.58 mg/m 2 ) on day 1 increased trabectedin dose-normalized AUC by 66% and C max by 22% compared to a single YONDELIS dose (1.3 mg/m 2 ) given alone.

Trabectedin + Lopinavir⚠️Major

Trabectedin + Nefazodone⚠️Major

Strong CYP3A inhibitor. Avoid concomitant use with trabectedin or time administration carefully if short-term use necessary.

Trabectedin + Nelfinavir⚠️Major

Trabectedin + Phenobarbital⚠️Major

Strong CYP3A inducer. Avoid concomitant use with trabectedin.

Trabectedin + Posaconazole⚠️Major

Trabectedin + Rifampin⚠️Major

Strong CYP3A inducer decreased trabectedin systemic exposure by 31%. Avoid concomitant use with trabectedin.

Trabectedin + Ritonavir⚠️Major

Trabectedin + Saquinavir⚠️Major

Trabectedin + St. John'S Wort⚠️Major

Strong CYP3A inducer. Avoid concomitant use with trabectedin.

Trabectedin + Telaprevir⚠️Major

Trabectedin + Telithromycin⚠️Major

Trabectedin + Voriconazole⚠️Major

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.